LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Blood Test Could Cut Hospital Stays for Children with Cancer

By LabMedica International staff writers
Posted on 21 Mar 2022
Print article
Image: Blood test could shorten hospital stays for children with cancer (Photo courtesy of University of York)
Image: Blood test could shorten hospital stays for children with cancer (Photo courtesy of University of York)

High temperatures are common in children undergoing treatment for cancer due to their lowered immune system. The commonest approach is to keep children in hospital for up to a week while antibiotics are administered in case the fever is a symptom of a serious infection like sepsis. A new blood test could help to safely cut hospital stays for children with cancer who develop a fever, according to a new study.

The study, by researchers from the University of York (York, UK) and Hull York Medical School (York, UK) reveals the blood test can help doctors to distinguish between children whose fever is a sign of serious illness and those who are safe to go home. The results of the study, which involved 28 children with cancer, show that using the blood test in combination with a new protocol to identify children that are safe to go home, cuts their average stay in hospital down to two days, with some able to leave in as little as eight hours. The researchers believe that this change will make an enormous difference to children with cancer and their families, easing mental health and financial burdens. The test diagnoses serious infections by looking at levels of the biomarker procalcitonin in the blood. Those children with low levels often had their antibiotics stopped more quickly and went home earlier.

"Frequent fevers are a distressing and sometimes life-threatening complication of childhood cancer. Our study shows that procalcitonin blood tests could make a big difference to children who don’t have a serious infection, allowing them to go home earlier to be with their families, cutting unnecessary treatment with antibiotics and reducing an already intense mental and physical toll," said Dr. Bob Phillips from the Centre for Reviews and Dissemination at the University of York and Hull York Medical School. "These promising results and the willingness of families to take part in this research mean we can now apply for further funding in order to carry out a large-scale study."

Related Links:
University of York 
Hull York Medical School 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.